

LA JOLLA PHARMACEUTICAL CO

Form 8-K

February 26, 2004

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): February 26, 2004

LA JOLLA PHARMACEUTICAL COMPANY

(Exact Name of Registrant as Specified in Charter)

Delaware

0-24274

33-0361285

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

6455 Nancy Ridge Drive
San Diego, California 92121
(Address of Principal Executive Offices, Including Zip Code)

Registrant's telephone number, including area code: (858) 452-6600

TABLE OF CONTENTS

Item 5. Other Events and Required FD Disclosure.

Item 7. Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

Table of Contents

Item 5. Other Events and Required FD Disclosure.

On February 26, 2004, La Jolla Pharmaceutical Company issued a press release announcing that it had completed its previously announced public offering of 8,695,653 shares of common stock. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 7. Exhibits.

(c) Exhibits:

The following exhibits are filed with this Report on Form 8-K:

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated February 26, 2004

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 26, 2004

LA JOLLA PHARMACEUTICAL
COMPANY

By: /s/ Steven B. Engle
Steven B. Engle
Chairman and Chief Executive Officer

Table of Contents

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated February 26, 2004